JACOBIO (01167.HK) holds cash reserves of 2.1 billion RMB and has spent approximately 34.17 million HKD on share repurchases to date.

JACOBIO (01167.HK) announced that it has recently received the first payment of USD 100 million from its strategic partner AstraZeneca (AZN.US), as well as a sales revenue share of RMB 8.55 million from Eli Lilly (688578.SH) for the period from June to December 2025. To date, the group’s total balance of cash and bank deposits, principal-guaranteed structured deposit investments, and available bank credit lines amounts to approximately RMB 2.1 billion, ensuring ample financial reserves. Based on the current cash reserves and controlled expenditure planning, the group’s cash runway extends for at least four years, providing sufficient support for the ongoing development of its core innovative oncology pipeline.

AASTOCKS08:34

Ellis Shareholders' Meeting: Heavy reliance on a single blockbuster product, with more growth anxieties to address amid the looming patent cliff.

① Once the growth dividend of Fumetinib begins to taper off, whether there will be a successor product and where Alis's "next Fumetinib" lies have become key focal points for the market; ② The domestic patent for the Fumetinib compound is set to expire in 2034, while the domestic patent for Methanesulfonic Acid Fumetinib (salt) will expire in 2036. **This implies that the existing patent protection barrier will vanish by then, and Alis may no longer enjoy the high gross profit margin associated with its original drug.**

cls.cnMay 16 21:41

Industrial Securities: Shift in Momentum for the Pharmaceutical Industry - Seizing Growth Opportunities from Industrial Innovation

Innovation and internationalization in the medical device sector are accelerating, with continuous emerging hotspots in industrial directions.

Zhitong FinanceMay 11 13:45

Alis (688578): Performance growth continues to exceed expectations, with coordinated growth in medical insurance products.

On April 23, 2026, the company announced its financial results for the fiscal year 2025 and the first quarter of 2026. In 2025, the company achieved operating revenue of 5.187 billion yuan, representing a year-on-year increase of 45.80%; net profit attributable to shareholders was...

Huaan SecuritiesMay 10 17:11

Alice (688578): Q1 results exceed expectations as product portfolio gradually takes shape.

The company announced its annual report for the year 25 and the first quarter report for the year 26. In year 25, revenue reached 5.19 billion yuan (+45.8%), net profit attributable to shareholders was 2.19 billion yuan (+53.1%), and non-recurring net profit attributable to shareholders was 2.02 billion yuan.

China Post SecuritiesMay 8 00:00

Ailis (688578): Research and sales synergy drives high efficiency, maintaining robust growth in performance.

In April 2026, Ellys released its 2025 annual report: For the full year of 2025, the company achieved total operating revenue of 5.187 billion yuan (a year-on-year increase of 45.80%) and net profit attributable to shareholders of 2.189 billion yuan (a year-on-year increase of

Changjiang SecuritiesMay 6 07:46